Anika Therapeutics, Inc. (ANIK) stock declined over -1.10% intraday to trade at $22.50 a share on NASDAQ. The stock opened with a gain of 1.31% at $22.64 and touched an intraday high of $22.75, falling -1.10% against the last close of $22.75. The stock went to a low of $22.35 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue147.79 Million
5Y Sales Change7.40%
Fiscal Year Ends2021-12-30
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Anika Therapeutics, Inc. (NASDAQ: ANIK) stock price is $22.5 as of the last check on Wednesday, July 6. During the trading session, ANIK stock reached the peak price of $22.75 while $22.35 was the lowest point it dropped to.
The NASDAQ listed ANIK is part of Biotechnology industry that operates in the broader Health Care sector. Anika Therapeutics, Inc. , together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally.
Mr. Thomas M. Finnerty
Exec. VP of HR
Mr. James Loerop
Exec. VP of Bus. Devel. & Strategic Planning
Dr. Cheryl Renee Blanchard Ph.D.
Pres, CEO & Director
Mr. Michael L. Levitz
Exec. VP, CFO & Treasurer
ANIK stock traded closed the last session at $22.5, which is $-0.25 or -1.10% lower than its previous close of $22.75. ANIK's current trading price is 12.78% lower than its 52-week high of $45.81 where as its distance from 52-week low of 19.95% is -50.88%.
Number of ANIK employees currently stands at -. ANIK operates from 32 Wiggins Avenue, Bedford, MA 01730, United States.
Official Webiste of $ANIK is: https://www.anikatherapeutics.com
ANIK stock volume for the day was 102,333 shares while in the previous session number of ANIK shares traded was 101,591 . The average number of ANIK shares traded daily for last 3 months was 111.48 Thousands.
The percentage change in ANIK stock occurred in the recent session was -1.10% while the dollar amount for the price change in ANIK stock was $-0.25.
In the recent session, the day high for ANIK stock was $22.75 while the low for ANIK stock touched on the day was $22.35.
The market value of ANIK currently stands at 324.45 Million with its latest stock price at $22.5 and 14.47 Million of its shares outstanding.